Town & Country Bank & Trust CO dba First Bankers Trust CO Has $641,000 Position in Pfizer Inc. (NYSE:PFE)

Town & Country Bank & Trust CO dba First Bankers Trust CO decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,294 shares of the biopharmaceutical company’s stock after selling 882 shares during the quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Pfizer were worth $641,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Vanguard Group Inc. grew its stake in Pfizer by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company’s stock valued at $13,756,738,000 after buying an additional 2,285,276 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock worth $4,124,330,000 after acquiring an additional 25,315,159 shares during the period. Geode Capital Management LLC grew its position in shares of Pfizer by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock valued at $3,190,131,000 after purchasing an additional 2,923,537 shares during the last quarter. Norges Bank bought a new position in shares of Pfizer during the fourth quarter worth approximately $2,328,986,000. Finally, Massachusetts Financial Services Co. MA lifted its holdings in Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on the company. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective for the company. Finally, UBS Group raised their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Stock Performance

Shares of Pfizer stock opened at $23.44 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market cap of $133.26 billion, a PE ratio of 16.62, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The company has a 50 day moving average of $23.16 and a 200-day moving average of $25.09. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same period in the prior year, the company earned $0.82 earnings per share. The company’s quarterly revenue was down 7.8% on a year-over-year basis. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.34%. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.